# Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic Sclerosis

> **NIH NIH R01** · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 2024 · $321,060

## Abstract

Systemic sclerosis (SSc-scleroderma) is a multisystem autoimmune, fibrotic disease associated with high
morbidity and mortality. Progress in the development of effective therapies for SSc has been hampered by a
fragmented understanding of its pathogenesis. Although abundant evidence implicates dysregulated immunity
in SSc, the mechanisms by which the immune system influences fibroblast function are not well-understood. We
propose herein a multifaceted approach to elucidate the role of interferon regulatory factor 7 (IRF7) in dermal
fibroblasts as a pathologic bridge between immune dysregulation and fibrosis in SSc.
An interferon (IFN) gene expression signature is the most prominent peripheral blood cell transcript profile in
SSc. Moreover, our large-scale gene expression studies have identified IRF7, a key transcription factor in the
type I IFN pathway, as the top predicted upstream regulator of the SSc molecular profile in both skin and blood,
as well as a prominent regulator of SSc fibroblasts. Our recently published work showed that IRF7 is significantly
upregulated and activated in SSc skin and explanted dermal fibroblasts, and that type I IFN upregulates IRF7
expression in fibroblasts. IRF7 interacts with SMAD3 and potentiates TGFβ induced fibrosis signaling in
fibroblasts. Moreover, global Irf7 knockdown attenuates dermal fibrosis in two murine dermal fibrosis models.
Lastly, our recent preliminary data suggest fibroblast specific Irf7 knockdown might be sufficient for attenuating
the bleomycin induced dermal fibrosis. Herein, we hypothesize that IRF7 links type I IFN pathway to the fibrotic
response by potentiating the TGFβ signaling in fibroblasts which are the primary effector cells in SSc. Our primary
goal is to elucidate the role of type I IFN induced IRF7 upregulation in potentiating the TGFβ canonical
pathway via IRF7 interaction with SMAD3 in dermal fibroblasts. The following Specific Aims will be pursued:
Aim 1: Define the fibroblast specific contribution of Irf7 depletion in murine dermal fibrosis models. The
impact of fibroblast specific Irf7 depletion on dermal fibrosis in bleomycin induced and Tsk1 dermal fibrosis
models will be investigated. Aim 2: Elucidate the functional effects of IRF7 on SMAD3 mediated
transcriptional activity and gene expression regulation Human fibroblast cell lines with IRF7 over-
expression and deletion will be generated and TGFβ-mediated SMAD3 transcriptional targets and gene
expression regulation will be characterized by ChIP- and RNA-sequencing. Aim 3: Delineate the relationship
between the peripheral blood cell interferon signature and IRF7 upregulation at the end-organ level in
patients with SSc. The relationship between the peripheral blood IFN signature and IRF7 expression in SSc
skin tissue and dermal fibroblast subpopulations will be characterized using bulk and single cell RNA sequencing.
Cumulatively, this proposal can elucidate a key mechanism by which immune dysregulation leading to IRF7
...

## Key facts

- **NIH application ID:** 10835058
- **Project number:** 5R01AR081280-02
- **Recipient organization:** UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- **Principal Investigator:** Shervin Assassi
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $321,060
- **Award type:** 5
- **Project period:** 2023-05-01 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10835058

## Citation

> US National Institutes of Health, RePORTER application 10835058, Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic Sclerosis (5R01AR081280-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10835058. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*